Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sanofi 2 ADR Representing Ord Shs SNY

Healthcare
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Recent & Breaking News (NDAQ:SNY)

Pharma M&A Picks Up Momentum

Benzinga.com  January 23, 2018

Mid-Afternoon Market Update: Bioverativ Climbs Following $105/Share Offer From Sanofi; Recon Technology Shares Drop

Benzinga.com  January 22, 2018

Mid-Day Market Update: Juno Therapeutics Surges On Acquisition News; Sanmina Shares Plummet

Benzinga.com  January 22, 2018

Benzinga Pro's 6 Stocks To Watch Today

Benzinga.com  January 22, 2018

Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc.

PR Newswire January 22, 2018

A Peek Into The Markets: U.S. Stock Futures Drop After Government Shutdown

Benzinga.com  January 22, 2018

8 Stocks To Watch For January 22, 2018

Benzinga.com  January 22, 2018

Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee

GlobeNewswire January 19, 2018

Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs

GlobeNewswire January 8, 2018

Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance

GlobeNewswire January 7, 2018

Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis

GlobeNewswire December 18, 2017

Sanofi: FDA lifts clinical hold on fitusiran

GlobeNewswire December 15, 2017

Sanofi : Sanofi presents R&D strategy and innovative pipeline

GlobeNewswire December 13, 2017

Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

GlobeNewswire December 13, 2017

The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value

Canada NewsWire December 12, 2017

FDA Approves Sanofi's Admelog® (insulin lispro injection)

GlobeNewswire December 11, 2017

Sanofi explores combination treatments for multiple myeloma in new late-stage trials

Business Wire December 7, 2017

Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec

GlobeNewswire December 4, 2017

Sanofi ends development of Clostridium difficile vaccine

GlobeNewswire December 1, 2017

Switching to Toujeo® in a real-world setting produced a similar number of severe low blood sugar events as insulin degludec

PR Newswire November 30, 2017